One step forward, two steps back: The story of everolimus in advanced breast cancer
- 1 October 2015
- journal article
- Published by Elsevier in The Breast
- Vol. 24 (5) , 529-531
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-AnalysisJournal of Clinical Oncology, 2014
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet Oncology, 2014
- Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.Journal of Clinical Oncology, 2013
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trialCancer, 2013
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO StudyJournal of Clinical Oncology, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast CancerJournal of Clinical Oncology, 2008